Definium Therapeutics (DFTX) Q3 2026 earnings summary

Executive summary

• DT120 met primary and key secondary endpoints in Phase 3 Voyage and Panorama for GAD and Emerge for MDD; FDA granted breakthrough therapy designations for GAD and MDD.

• DT120 NDA filing remains targeted for H1 2027, with commercial-readiness work advancing across access, distribution, patient services and provider readiness.

• Initial DT402 Phase 2a findings in five adults with ASD showed exploratory improvements across socialization, communication and functional measures; a multiple-dosing study is planned for 2027.

Financial highlights

• Q3 2026 R&D expense was $46.1M vs. $31.0M in Q3 2025; G&A was $26.1M vs. $14.7M, lifting operating expenses to $72.3M from $45.7M.

• Q3 net loss was $51.0M vs. $67.3M; 9M net loss was $287.0M vs. $133.4M, including a $93.9M warrant fair-value expense in 9M 2026.

• Q3 net loss benefited from a $12.4M warrant fair-value gain and higher interest income, partly offset by higher operating expenses.

• Cash, cash equivalents and investments totaled $1.05B at September 30, 2026, vs. $411.6M at December 31, 2025; no revenue had been generated.

• 9M operating cash use was $148.4M; investing activities used $647.5M and financing activities provided $779.2M.

Outlook and guidance

• September 30, 2026 cash, cash equivalents and investments are expected to fund operations into 2030 under the current operating plan and anticipated milestones.

• DT120 NDA filing is targeted for H1 2027; Ascend MDD Part A topline results are expected in 2027, with enrollment continuing.

• Phase 3 Haven PTSD study is planned to start in 2027, targeting ~200 participants, with Week 8 CAPS-5 change as the primary endpoint.

• A DT402 multiple-dosing study and a Commercial Day are planned for 2027 and H1 2027, respectively.

• R&D and G&A expenses are expected to rise as clinical development and commercial preparation advance.